$OMC

Novo Nordisk appointed Omnicom as agency of record for its US media account after ending its WPP partnership. The move supports expanded consumer engagement for GLP-1 drugs Ozempic and Wegovy. Reuters data cited by the article says Novo Nordisk spent about $500m on advertising for Wegovy and Ozempic in the first nine months of 2025, over double Eli Lilly’s.

Publicis Groupe said it will acquire LiveRamp for $2.167 billion, framing LiveRamp’s identity technology as neutral by design. Omnicom accelerated its LiveRamp contract termination and WPP said it stopped using LiveRamp. The article argues ad holding companies are building proprietary identity infrastructure, affecting data sharing and activation strategies.

Simply Wall St reports Omnicom Group (OMC) posted stronger Q2 2026 results versus a year earlier, with higher sales, net income, and EPS, alongside an active buyback. It cites a 30-day return of 8.45% and 90-day return of 10.62%. The article discusses valuation versus fair value ($102.83 vs $85.24) and an Interpublic acquisition/integration.

Novo Nordisk said it will move its US media buying account from WPP’s Wavemaker to Omnicom, effective in Q4 2026, after a competitive review, covering media planning and buying for its portfolio including Ozempic and Wegovy. Novo Nordisk expects Omnicom to manage US operations. COMvergence estimates annual US media spend at over $600 million.

Omnicom Media Asia appointed adtech and media veteran Ricky Chanana as senior vice president, Commercial, to expand adoption of Omnicom Media’s commercial products Omnet, Orion and Outcomes across Asia-Pacific. The role shares the regional portfolio with Simon Flaxman for Australia and New Zealand. Omnicom said the hire supports commercial growth following its late-2023 acquisition of IPG Mediabrands.

Omnicom won a U.S. media account for Novo Nordisk, the maker of GLP-1 drugs Ozempic and Wegovy, according to the article. Novo Nordisk said it will work with Omnicom to scale consumer-focused strategies. COMvergence data cited values of $618 million globally and $520 million for the U.S. account.

Omnicom Group’s Q2 results beat revenue estimates, with revenue of $6.56B vs $6.44B expected and organic revenue up 6.1% year on year, but adjusted EBITDA of $1.13B missed estimates. Management attributed performance to Interpublic asset integration and growth in integrated media and experiential marketing. Analysts questioned growth sustainability, margin flow-through, and asset dispositions. OMC shares fell after earnings.

Omnicom reported Q2 ended June 30, 2026 revenue of $6.6B and core operations revenue of $6.0B, up 6.1% organically. Non-GAAP adjusted EBITA rose to $1.1B, margin 17.8%. Adjusted diluted EPS increased 29% to $2.65. Operating income and net income also rose, with results tied to IPG integration and cost efficiencies.

Omnicom (OMC) is trading around $79.61 and has gained 11.4% over the past year. The article says its trailing free-cash-flow yield is 10.7%, about 6.1 percentage points above the 4.7% Treasury rate, with net debt to equity of 0.36. Omnicom raised 2026 organic revenue growth guidance for ongoing operations to 5% from 4% to 4.5%, citing its post-merger strategy.

Omnicom Group Inc. (OMC) reported adjusted Q2 2026 EPS of $2.65 and revenue of $6.56B, both above consensus, with 6.1% organic growth. The FY2026 earnings estimate fell 5.6% over four weeks. The article cites net interest expense rising to $93.3M and a $79.61 price vs $68 target, plus a $3.20 dividend and $1.50B FCF.